Comparative Pharmacology
Head-to-head clinical analysis: EPIDIOLEX versus FELBATOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPIDIOLEX versus FELBATOL.
EPIDIOLEX vs FELBATOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cannabidiol is a cannabinoid with anticonvulsant properties. Its exact mechanism is unknown but may involve modulation of neuronal calcium channels, inhibition of adenosine reuptake, and agonism of 5-HT1A receptors.
Felbamate is a GABA receptor agonist and modulates NMDA receptor activity, though its exact mechanism is not fully understood. It appears to enhance GABA-mediated inhibition and inhibit voltage-gated sodium channels, reducing neuronal excitability.
Initial 2.5 mg/kg orally twice daily; after 1 week, increase to 5 mg/kg twice daily; may titrate to 10 mg/kg twice daily based on tolerability and efficacy. Maximum dose: 20 mg/kg daily.
1200-3600 mg/day orally in 3-4 divided doses; initial titration recommended.
None Documented
None Documented
The terminal elimination half-life of cannabidiol following oral administration is approximately 56-61 hours in healthy volunteers and 31-40 hours in patients with epilepsy. This long half-life supports once-daily dosing for chronic conditions.
20-23 hours; steady state reached within 3-5 days; may be prolonged in hepatic impairment.
Cannabidiol (CBD) is primarily eliminated via fecal excretion (approximately 73-94% of the dose) as unchanged drug and metabolites, with renal excretion accounting for less than 5% of the dose. Biliary excretion contributes to fecal elimination.
Renal: 40-50% unchanged; Hepatic metabolism accounts for ~50% with glucuronidation and oxidation; minimal biliary/fecal excretion (<5%).
Category C
Category C
Anticonvulsant
Anticonvulsant